Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 4,501–4,600 of 4,628
Bui, P., Onge, E. S., Sotolongo-Miranda, H., & Trabulsi, T. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261447319
Newton, C. A. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag237
Objective clinical scoring system and diagnostic variability in idiopathic pulmonary fibrosis
Abecassis, C., Pastré, J., Case, A., et al. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04293-0
Lactic acid and Lactylation in the Progression of Pulmonary Fibrosis
Wang, F., Jiang, M., Zhu, L., Liu, J., Tang, J., Jin, X., Liu, H., Cheng, Z., Wang, Z., Liu, R., et al. (2026) · BIO Integration · doi:10.15212/bioi-2026-0009 · Cited by 1
Sun, C.-Y., Yang, W., Shen, H., Yu, W.-K., Chen, W.-C., & Yang, K. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s569219
Pulmonary manifestations in rheumatoid arthritis
Conway, R. P., & Harrington, R. (2026) · Technical report · doi:10.1016/b978-0-443-23722-5.00001-7
Kølner-Augustson, L., Altraja, A., Bendstrup, E. M., Bradding, P., Østergård, N. M., Wilson, A. C., Simonsen, U., & Hilberg, O. (2026) · Diagnostics · doi:10.3390/diagnostics16111649
Güler, N., Alpaydın, A. Ö., Tertemiz, K. C., Sevinç, C., Ellıdokuz, H., Şimşek, G. Ö., & Uçan, E. S. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04373-1
Torok, K. S., & Foeldvari, I. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11980-4.00031-3
Patil, V. S., Patil, C. R., Paul, R., Gaikwad, A., Patil, K., & Kumar, A. (2026) · Personalized Medicine · doi:10.1080/17410541.2026.2679985
國府, 拓., Kokubu, H., Takeuchi, S., Tozawa, T., Hisada, S., Yamada, Y., ITOH, Y., & Kodera, M. (2023) · Institutional Repositories DataBase (IRDB)
Pulmonary fibrosis: evolving therapeutic pipeline
Shannon, L., Islam, S., Hilary, B., Murphy, G., Bailey, S., Rooney, R., & Chaudhuri, N. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-001886
Hirsch, T. I., Miller, W. P., Tsikis, S. T., Arévalo-Alquichire, S., Kaplan, B. A., Barake, K. W., Gunawan, A. L., Vanderleest, T. E., Vijikumar, A., Sanchez-Suarez, J., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-55553-2
Improved time to antifibrotic approval using an online drug application portal
Luu, B., & Fidler, L. (2026) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2026.2668051
“5,9,12 Unfortunately, barriers to accessing antifibrotics may exist; prolonged wait times to specialist consultation, high costs and wait times for drug approval can contribute to delayed access.”
Dong, S., Li, X., Zhang, W., Chen, X., & Lu, Y. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s588785
Lee, J. M., Kim, K. T., Lee, C., & Hwang, H. S. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18060668
“Nevertheless, neither therapy halts disease progression in most patients, and treatment is frequently limited by gastrointestinal and hepatic adverse effects, poor tolerability, and high cost, leading to dose reduction or discontinuation in real-world settings [15–17].”
Yang, J., Fee, R. M., Steffens, A., Le, L., Bui, B. H., & Borah, B. J. (2026) · Journal of health economics and outcomes research · doi:10.36469/jheor.2026.161503
Chee, M., Khor, Y. H., Jackson, D., Cooper, W., D'Costa, J., de Boer, S., Edwards, A., Ellis, S. J., Gabbay, E., Gallagher, H., et al. (2026) · Internal Medicine Journal · doi:10.1111/imj.70490
Goda, S., Yamada, T., Goto, Y., Uda, S., Nakao, A., Shiotsu, S., Kukida, Y., Tanimura, K., Miyamoto, A., Imasato, Y., et al. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101463
Zhang, S.-M., Huang, M.-Z., Wang, Y.-W., Wang, X.-F., Ding, Y., Li, J. Q., Zou, X.-M., & Ma, C. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.108946 · Cited by 2
Riccò, B., Grisendi, G., Monaco, A. L., Giuggioli, D., Clini, E. M., & Dominici, M. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119626 · Cited by 1
CTHRC1: a serum biomarker for a pathological fibroblast in IPF
Khatri, A., & Todd, J. L. (2026) · Thorax · doi:10.1136/thorax-2026-225250
Panopoulos, S., Poulia, V., Vlachogiannis, N. I., et al. (2026) · Rheumatology International · doi:10.1007/s00296-026-06173-6
Wang, W., Gu, Y., & Mo, L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1875852
Terzıoğlu, E. (2026) · European Respiratory Journal · doi:10.1183/13993003.00610-2026
S100A4 Orchestrates Fibroblast Fate to Drive Fibrotic Remodeling
Li, S., Cai, B., Zhang, X., Cai, G., Zhou, Y., Wagener, B. M., & Ding, Q. (2026) · The FASEB Journal · doi:10.1096/fj.202600886r
Protective effects of PRELP protein in a mouse model of pulmonary fibrosis
Yuki, M., Ishimori, T., Youichi, S., Kosuge, H., Okuda, K., Hattori, M., Shuzui, M., Saito, M., Isago, H., Tamiya, H., et al. (2026) · Respiratory Research · doi:10.1186/s12931-026-03760-w · Cited by 1
Nag, S., Thakur, D., & Sharma, K. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2688859
Global landscape for pulmonary fibrosis treatment: a data-driven perspective from clinical trials
Zhao, C., Song, C., Zhou, Y., Luo, J., Zheng, S., Li, X., Dang, Y., Yang, N., & Kong, J. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04340-w
Deterding, R. R., Young, L. R., DeBoer, E. M., Warburton, D., Cunningham, S., Schwerk, N., Brown, K. K., Koucký, V., Weinman, J. P., Simmons, J., et al. (2026) · Pediatric Pulmonology · doi:10.1002/ppul.71707 · Cited by 2
“As observed in trials of nintedanib in adults [9–11], and in the InPedILD trial [13], the most frequent adverse event in InPedILD‐”
Self-citationAcute Exacerbation of Interstitial Lung Disease: A Case Series and a Narrative Literature Review
Czyżak, B., Lasota, A., & Majewski, S. (2026) · Advances in respiratory medicine · doi:10.3390/arm94030042
“Furthermore, patients treated with nintedanib experienced fewer episodes of multiple AEs than those in the placebo group (4.6% vs. 8.7%, respectively) [49].”
InfluentialTherapie der idiopathischen Lungenfibrose: Langzeiteffektivität von Nerandomilast
Gillissen, A. (2026) · Pneumo News · doi:10.1007/s15033-026-4323-3
The role of macrophage-myofibroblast transition in the pathogenesis of multi-organ fibrosis
Guo, C., Cao, R., Liao, L., Zhao, J., Wang, T., Li, J. J., Zhang, Y., & Li, H. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103702
Kim, D. K. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.26.0058
Self-citationTranslational Insights into Phytoceutical-Based Pulmonary Drug Delivery for Fibrosis Therapy
Joshi, D., Shukla, P., & Vishwakarma, S. (2026) · International Journal of Newgen Research in Pharmacy & Healthcare · doi:10.61554/ijnrph.v4i1.2026.215
Targeted DNA triplex-forming oligonucleotide liposome for pulmonary fibrosis gene therapy
Xu, J., Xie, Y., Luo, Q., Ren, Y., Wang, J., Qin, C., Li, P., Liu, Y., Cheng, Y., Jiang, M., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102909
Doggrell, S. A. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2698522
“The fibrosis in IPF is treated with anti-fibrotic agents such as pirfenidone and nintedanib, and the use of these agents is limited by adverse effects, predominantly diarrhea (60% of subjects taking nintedanib in IPF [11]).”
Stiefer, A., Howard, A., Neely, M. L., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10007120/v1
Nasiri, H., Khosravi, F., Eskandari, F., Manoochehrabadi, T., Samadikuchaksaraei, A., Lotfi, E., Majidi, J., Rafati, F., & Ghorbani, Z. (2026) · Clinical and Translational Discovery · doi:10.1002/ctd2.70172
Yabuuchi, H., Sagiyama, K., Tsubouchi, K., Hashisako, M., Takano, T., Yamasaki, Y., Hida, T., Hino, T., Tashiro, K., Nishizawa, N., et al. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.109022
Fay, C. (2026) · Academic Medicine & Surgery · doi:10.62186/001c.163657
Koschel, D., Behr, J., & Bonella, F. (2026) · Pneumologie · doi:10.1055/a-2883-1874
Mu, J., Ding, Y. P., Yu, Y., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1874765
Fibrotic chronic eosinophilic pneumonia: from inflammation to fibrosis and therapeutic implications
Previtero, D., Castelli, G., Padrin, Y., Scalvenzi, F., Ruzzon, I., Cocconcelli, E., Tinè, M., Balestro, E., Padoan, R., Caminati, M., et al. (2026) · European Respiratory Review · doi:10.1183/16000617.0076-2026 · Cited by 1
Sharata, E. E., Abdelnaser, M., Bakry, T., Hassan, M. A., William, N. S., Yasser, V., Rashad, M. S., Tadres, K. E., & Mohyeldin, R. H. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05688-w · Cited by 1
Ogasawara, T., Hiraoka, Y., Muramatsu, T., Kishimoto, E., Nagasaki, K., Matsuyama, W., Suzuki, T., Niwa, M., Ozawa, Y., & Sato, J. (2026) · Next research. · doi:10.1016/j.nexres.2026.102149
Barbosa, B. J. P., de Poll, C. M. V., & Oliveira, E. R. D. S. (2026) · Aracê. · doi:10.56238/arev8n7-055
Epithelial Stem Cell Fate Determines Chemoradiotherapy Response in Rectal CancerPreprint
Li, N., Ishaqwala, F., Wright, T. A., Wilkinson, A., Vlckova, P., Trevers, K. E., O’Sullivan, R., Crampsie, S., Basiarz, E., Vanderkamp, S., et al. (2026) · SSRN Electronic Journal · doi:10.64898/2026.07.15.736775
Interstitial Lung Disease In Older Adults
Chiang, G. C., Shao, S., & Antin-Ozerkis, D. E. (2026) · Respiratory medicine · doi:10.1007/978-3-032-29861-4_15
Precision Modulation of the PDE4 Pathway: The Emerging Role of Nerandomilast in Pulmonary Fibrosis
Bishop, K. N., Santana, J. M., Dietrich, E., et al. (2026) · Journal of Pharmacy Technology · doi:10.1177/87551225261466572
Optimization of Therapeutic modRNA Delivery to the Lung for Prevention of Pulmonary Fibrosis
Mainkar, G., Żak, M. M., Ghiringhelli, M., Yoo, J., Adjmi, M., Kaur, K., & Zangi, L. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070868
Althobiani, M. A., Alahmadi, H. I., Almaghlouth, F., Zafir, T., Alshamrani, A., Alalawi, Z., Homoud, M. M., Alghamdi, H., Bintalib, H. M., Aljehani, M., et al. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1830926
Mocci, S., Mereu, C., Littera, R., Deidda, S., Cannas, F., Lorrai, M., Zedda, E., Murgia, M., Sanna, C., Giuressi, E., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1722213
Paliogiannis, P., Zoroddu, S., Fois, S., Scala, C., Zinellu, E., Mangoni, A. A., Carru, C., Pirina, P., Zinellu, A., & Fois, A. G. (2026) · Antioxidants · doi:10.3390/antiox15080923
“At the same time, the observed heterogeneity in disease progression warrants the identification of robust prognostic biomarkers to inform clinical decision making and monitoring [6–8].”
Zhang, X., Chen, Y., Cai, S., Ye, C., Hu, Z., Zhang, Z., Wang, Y., Hu, Q., & Dong, L. (2026) · Clinical Rheumatology · doi:10.1007/s10067-026-08315-4
Decorin and IL-10 co-overexpression in BMDMSCs attenuates pulmonary fibrosis – an experimental study
Yue, Y., Lin, K., Fang, W.-F., Shao, P., Huang, C., Chen, Y., Wang, Y.-T., Yip, H., & Lee, M. S.-S. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000005530
Child, C. E., Ho, L. A., Borders, E., Gray, T., Olson, T., Gordon, B., Cai, H. D., Veras-Tobos, E., Traylor, K., Babu, G., et al. (2026) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2026.07.019
Self-citationOmran, O., Kalra, A., Muelly, M. C., Reicher, J. J., & Ahmed, R. (2026) · Diagnostics · doi:10.3390/diagnostics16152398
“…interval from initial assessment to final diagnosis in this cohort was 213 days [3], an earlier indication could shorten the diagnostic timeline and accelerate access to antifibrotic therapy, which slows lung-function decline in IPF [30,31] and across progressive fibrosing ILD more broadly [32].”
Wang, W., Zhang, Y., He, F., Sun, L., Li, H., Liu, R., Zhong, G., Zhang, L., Li, A., Feng, M., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02753-x · Cited by 1
A self-sustaining repair circuit drives the progression of pulmonary fibrosis
Bach, D., Nguyen, T. K., Pham-The, H., & Nguyen, T. L. (2026) · Translational research · doi:10.1016/j.trsl.2026.07.015 · Cited by 1
Tambe, A. P., Boente, R., George, G., Kheir, F. M., Omran, O., & Selvan, K. C. (2026) · Diagnostics · doi:10.3390/diagnostics16152445
Jia, Y., Liu, W., Tang, W., Ou, S., Na, W., Dong, M., & Wei, Y. (2026) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666261475569
A novel in vitro assay for quantifying endothelial cell and pericyte interactionsPreprint
Csordas, D. J., Cucuzzella, L. C., Kim, J. S., & Peirce, S. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.03.742618
Li, Z., Song, D., Sun, F., Song, L., An, B., Gao, T., Liu, J., Zhang, K., Liu, K., Wu, K., et al. (2026) · Cell Proliferation · doi:10.1111/cpr.70267
STARSHIP: Study of Telomeres And Role of Sex Hormones In Pulmonary fibrosisPreprint
Duckworth, A., Prague, J., Knight, B., Norris, K., Emms, H., Goodrum, S., Crook, C., Sayers, R. R., Steward, M., Thould, H., et al. (2026) · medRxiv · doi:10.64898/2026.08.03.26359301
Srivastava, V. (2026) · Research Square · doi:10.21203/rs.3.rs-10597751/v1
Lee, J. H., Kim, N. Y., Choi, C., & Yeon, M. (2026) · Biomedicines · doi:10.3390/biomedicines14081776
“Nintedanib, in particular, is already approved for use in both IPF and advanced non-small cell lung cancer, providing a precedent for dual-indication deployment that could be directly relevant to patients with post-infectious fibrosis who subsequently develop malignancy [138].”
Bassi, I., Carpano, M., Giancotti, G., et al. (2026) · Thorax · doi:10.1136/thorax-2026-225408
Patil, S. V., GONDHALI, G., & Patil, R. (2026) · Research Square · doi:10.21203/rs.3.rs-10460191/v1
Heo, S.-W., Choi, J., Song, Y., et al. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179224
Prognostic nutritional index predicts nintedanib outcomes in idiopathic pulmonary fibrosis
Hayakawa, E., Kato, M., HIRANO, H., et al. (2026) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666261478394
Bonella, F., & Majewski, S. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoag133
Yu, X., 沈凯石, Zhou, L., Li, X., Lin, X., Zhang, Y., Guan, Y., Deng, B., Chen, L., He, X., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-112091
Murine models of pulmonary fibrosis: mechanisms, limitations and translational insights
Lou, K. F., Fulcer, M. M., Lotesto, M. J., Davis, J. M., Serrano, T. P. O., Ma, R., & Ridge, K. M. (2026) · European Respiratory Review · doi:10.1183/16000617.0033-2026
Rukonge, P. A., Kawuribi, V., Lu, Z., Oluwaseun, A. F., Sheng, Y., Yan, K., Zheng, Z., Liu, X., Chu, L., & Yu, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1889276
Deng, R., Jiang, S., Han, X., Xiong, M., & Yang, X. (2026) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2026.08.004 · Cited by 1
Sato, Y., Kamio, K., Terasaki, Y., Yoshida, K., Kuse, N., Matsuda, K., Kajimoto, Y., Atsumi, K., Kaburaki, S., Tanaka, T., et al. (2026) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00168.2025
Djurdjevic, N., Pjević, M. D., Stjepanović, M., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177546
“As promising results were obtained, further research was continued [29,30].”
Mesenchymal Stem Cell Therapy for Idiopathic Pulmonary Fibrosis: Advances and Perspectives
Zou, Y. (2026) · BIO Web of Conferences · doi:10.1051/bioconf/202625001015
Kinoshita, Y., Ogata, R., Eshima, K., et al. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101504
Ren, M., Guihua, S. O. N. G., Xu, Y., Yu, S., Zhang, Y., Sun, M., & Zhang, B. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1914253
“Phase III trials showed that both drugs slow forced vital capacity decline or disease progression in IPF, but neither is curative (Richeldi et al., 2014; King et al., 2014).”
Ge, C., & Cui, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177649
Oral Nintedanib for Refractory Generalized Keloids: A Prospective Exploratory Pilot Study
Liu, C., Zhang, L., Sun, D., Lin, A., He, R., & Yang, B. (2026) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.71107
Turan, O., Uğurlu, E., Tapan, Ö. O., Sarıoğlu, N., Polat, G., Çilekar, Ş., Batum, Ö., & Gülen, Ş. T. (2026) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666261475558 · Cited by 2
Alghulayqah, A. (2026) · Cureus · doi:10.7759/cureus.115529 · Cited by 1
“The clinical efficacy of nintedanib was established in the pivotal INPULSIS program, comprising two parallel 52-week phase 3 trials (INPULSIS-1 and INPULSIS-2) that enrolled a total of 1,066 patients with IPF who were randomized 3:2 to nintedanib 150 mg twice daily or placebo [8].”
Wang, X., Liu, J., & Sang, A. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154515
Moran-MacDonald, A., Alyami, S., Aldhaheri, S., Kish, M., Davison, S., & Moran‐Mendoza, O. (2026) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-002726
Kim, M. J., Kwak, H. S., Kim, S., & Kim, H. C. (2026) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666261484857
The regulatory logic linking inflammation and fibrosis
Alexanian, M., & Srivastava, D. (2026) · Cell · doi:10.1016/j.cell.2026.08.001 · Cited by 3
Li, M., Wu, Z., Zheng, X., Zhu, Y., Wu, Y., He, J., Wu, X., Xu, J., & Qin, Y. (2026) · Current Treatment Options in Oncology · doi:10.1007/s11864-026-01412-1
Yang, Y., 刘森玉, Wang, S., Zhang, A., Wang, W., Zhu, Z., Zhang, X., & Liu, X. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108437
Gong, K., Zhu, J., Guo, H., Xu, M., Sun, T., Li, Z., Liu, Y., Li, L., Zhang, Y., Liu, C., et al. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05852-2
Automated CT-Based Quantification of Pulmonary Fibrosis Using Deep Learning-Based Lung Segmentation
Cheng, W., Liao, W.-C., Chen, C., et al. (2026) · Diagnostics · doi:10.3390/diagnostics16182907
Normal age-related decline in forced vital capacity: a systematic review and meta-analysis
Satia, I., Brown, K., Filkowski, J., et al. (2026) · European Respiratory Review · doi:10.1183/16000617.0329-2025
Self-citationHepcidin as a Biomarker of Response to Antifibrotic Therapy in Idiopathic Pulmonary Fibrosis
Yilmaz, G., Çoban, H., Erel, F., Akış, M., Sarıoğlu, N., Colak, M., & Şenel, M. Y. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187023
“Pirfenidone and nintedanib are approved antifibrotic drugs in the treatment of IPF and have been in clinical use since 2014 [5,6].”
Nagaoka, S., Hara, Y., Fujii, H., et al. (2026) · Canadian Respiratory Journal · doi:10.1155/carj/3604892
Serum GDF15 adds prognostic value to forced vital capacity in fibrotic interstitial lung disease
Suzuki, Y., Yoshimura, K., Mori, K., Kono, M., Matsushima, S., Kato, S., Suzuki, K., Tanaka, K., Koda, K., Masuda, T., et al. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101510
Self-citationPitozzi, V., Caruso, P., Pontis, S., Ruscitti, F., Pittelli, M. G., Aquino, G., Volta, R., Pappani, A., Barrea, M., Quaini, F., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188158
“Similarly, nintedanib, a multi-target tyrosine kinase inhibitor acting on Platelet-Derived Growth Factor (PDGF), FGF, and VEGF receptor pathways, at 150 mg twice daily (300 mg/day), attenuates FVC decline [4].”
Tu, Q., Zhang, X., Zou, Y., Lv, Y., Yan, L., Hou, C., Wang, L., Sun, W., Zhang, H., Pan, M., et al. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1884390
Arai, T., Hirose, M., Kobayashi, T., Shintani, R., Shintani, S., Inoue, Y., & Tachibana, K. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101513
Self-citation
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.